Merck KGaA (MKGAF)
164.00
+0.55
(+0.34%)
USD |
OTCM |
Aug 25, 16:00
Merck Enterprise Value : 83.26B for Aug. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 25, 2026 | 83.26B |
| August 24, 2026 | 83.03B |
| August 21, 2026 | 82.92B |
| August 20, 2026 | 82.45B |
| August 19, 2026 | 83.05B |
| August 18, 2026 | 81.62B |
| August 17, 2026 | 80.76B |
| August 14, 2026 | 80.92B |
| August 13, 2026 | 82.61B |
| August 12, 2026 | 83.05B |
| August 11, 2026 | 83.05B |
| August 10, 2026 | 84.31B |
| August 07, 2026 | 84.92B |
| August 06, 2026 | 85.00B |
| August 05, 2026 | 85.74B |
| August 04, 2026 | 86.13B |
| August 03, 2026 | 83.70B |
| July 31, 2026 | 85.40B |
| July 30, 2026 | 85.49B |
| July 29, 2026 | 84.24B |
| July 28, 2026 | 84.79B |
| July 27, 2026 | 82.92B |
| July 24, 2026 | 81.49B |
| July 23, 2026 | 81.58B |
| July 22, 2026 | 78.95B |
| Date | Value |
|---|---|
| July 21, 2026 | 79.22B |
| July 20, 2026 | 81.07B |
| July 17, 2026 | 80.88B |
| July 16, 2026 | 79.32B |
| July 15, 2026 | 81.96B |
| July 14, 2026 | 81.42B |
| July 13, 2026 | 81.83B |
| July 10, 2026 | 83.33B |
| July 09, 2026 | 82.05B |
| July 08, 2026 | 82.16B |
| July 07, 2026 | 84.62B |
| July 06, 2026 | 84.26B |
| July 02, 2026 | 85.87B |
| July 01, 2026 | 84.10B |
| June 30, 2026 | 85.87B |
| June 29, 2026 | 86.79B |
| June 26, 2026 | 84.06B |
| June 25, 2026 | 80.96B |
| June 24, 2026 | 81.56B |
| June 23, 2026 | 78.50B |
| June 22, 2026 | 75.70B |
| June 18, 2026 | 79.11B |
| June 17, 2026 | 77.37B |
| June 16, 2026 | 75.56B |
| June 15, 2026 | 78.28B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| STRATEC SE | 1.910B |
| Sartorius AG | 15.64B |
| Petros Pharmaceuticals, Inc. | -3.277M |
| Danaher Corp. | 175.33B |
| Illumina, Inc. | 35.33B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 574.38M |
| Revenue (Quarterly) | 6.318B |
| Total Expenses (Quarterly) | 5.748B |
| EPS Diluted (Quarterly) | 1.310 |
| Gross Profit Margin (Quarterly) | 58.26% |
| Profit Margin (Quarterly) | 9.09% |
| Earnings Yield | 3.88% |
| Operating Earnings Yield | 6.80% |
| Normalized Earnings Yield | 4.574 |